Market research
PTGX Protagonist Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 10B
- P/E ratio
- 149.83
- Analyst target
- 170.3846
- Dividend yield
- Not available
- Beta
- 1.79
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US74366E1029
- Market cap
- 10B
- P/E ratio
- 149.83
- Analyst target
- 170.3846
- Dividend yield
- Not available
- Beta
- 1.79
About
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PTGX discussion.
5 years, 4 months ago
Protagonist Therapeutics, Inc is currently in a long term uptrend where the price is trading 67.6% above its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 32.1.
Protagonist Therapeutics, Inc's total revenue rose by 107.8% to $6M since the same quarter in the previous year.
Its net income has dropped by 7.9% to $-19M since the same quarter in the previous year.
Finally, its free cash flow fell by 30.9% to $-19M since the same quarter in the previous year.
Based on the above factors, Protagonist Therapeutics, Inc gets an overall score of 3/5.